LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $112.60.

A number of research analysts have recently commented on the company. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Wells Fargo & Company boosted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Barrington Research reaffirmed an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Citizens Jmp increased their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 54,453 shares of company stock valued at $5,906,174 in the last 90 days. 7.40% of the stock is currently owned by company insiders.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently added to or reduced their stakes in the stock. Annex Advisory Services LLC grew its position in shares of LeMaitre Vascular by 6.0% during the 4th quarter. Annex Advisory Services LLC now owns 243,709 shares of the medical instruments supplier’s stock valued at $19,765,000 after purchasing an additional 13,692 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of LeMaitre Vascular in the third quarter worth $6,056,000. Wakefield Asset Management LLLP bought a new stake in LeMaitre Vascular during the fourth quarter valued at $1,130,000. Congress Asset Management Co. boosted its stake in LeMaitre Vascular by 5.8% during the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. Finally, Kennedy Capital Management LLC grew its position in LeMaitre Vascular by 14.8% during the fourth quarter. Kennedy Capital Management LLC now owns 247,907 shares of the medical instruments supplier’s stock worth $20,105,000 after buying an additional 32,040 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded up $1.17 during mid-day trading on Tuesday, reaching $104.89. The company had a trading volume of 129,046 shares, compared to its average volume of 249,295. LeMaitre Vascular has a one year low of $79.00 and a one year high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $98.60 and its 200-day moving average price is $97.43. The firm has a market cap of $2.40 billion, a price-to-earnings ratio of 38.71, a PEG ratio of 2.86 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same period in the prior year, the company earned $0.48 earnings per share. LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular will post 3 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were issued a $0.25 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 annualized dividend and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.